Alkermes, Inc.
Clinical trials sponsored by Alkermes, Inc., explained in plain language.
-
New drug shows promise for reducing narcolepsy sleep attacks
Disease control CompletedThis study tested an experimental medication called ALKS 2680 for people with narcolepsy type 1, a sleep disorder that causes severe daytime sleepiness and sudden muscle weakness (cataplexy). Researchers compared the drug against a placebo in 92 participants over 6 weeks to see i…
Phase: PHASE2 • Sponsor: Alkermes, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New pill tested to fight narcolepsy sleepiness
Symptom relief CompletedThis study tested whether a new tablet called ALKS 2680 could safely reduce excessive daytime sleepiness in adults with narcolepsy type 2. Researchers compared the drug against placebo pills in 93 participants to see if it helped people stay awake longer and feel less sleepy. Par…
Phase: PHASE2 • Sponsor: Alkermes, Inc. • Aim: Symptom relief
Last updated Mar 31, 2026 12:11 UTC